MBX Biosciences, Inc.
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 25.20% | 26.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.11% | 17.73% | |||
| Operating Income | 5.11% | -17.73% | |||
| Income Before Tax | 14.09% | -14.41% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 14.09% | -14.41% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 14.09% | -14.41% | |||
| EBIT | 5.11% | -17.73% | |||
| EBITDA | 5.04% | -17.73% | |||
| EPS Basic | 83.24% | 77.94% | |||
| Normalized Basic EPS | 80.09% | 77.94% | |||
| EPS Diluted | 83.24% | 77.94% | |||
| Normalized Diluted EPS | 80.09% | 77.94% | |||
| Average Basic Shares Outstanding | 412.50% | 418.51% | |||
| Average Diluted Shares Outstanding | 412.50% | 418.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||